Genelux Corp. (GNLX): Price and Financial Metrics
GNLX Price/Volume Stats
| Current price | $3.40 | 52-week high | $40.98 |
| Prev. close | $3.32 | 52-week low | $3.07 |
| Day low | $3.22 | Volume | 85,000 |
| Day high | $3.42 | Avg. volume | 125,217 |
| 50-day MA | $5.71 | Dividend yield | N/A |
| 200-day MA | $15.00 | Market Cap | 91.34M |
GNLX Stock Price Chart Interactive Chart >
Latest GNLX News From Around the Web
Below are the latest news stories about GENELUX CORP that investors may wish to consider to help them evaluate GNLX as an investment opportunity.
Insider Sell Alert: Director James Tyree Offloads 9,000 Shares of Genelux Corp (GNLX)In the realm of stock market movements, insider trading activity is often a significant indicator for investors. |
Genelux Corporation Receives FDA Fast Track Designation for Olvi-Vec in Platinum Resistant/Refractory Ovarian Cancer- Pivotal Phase 3 Study of Olvi-Vec in Platinum Resistant/Refractory Ovarian Cancer Initiated in September 2022 - - Phase 2 Trial of Olvi-Vec- Demonstrated Clinical Reversal of Platinum Resistance and Refractoriness and Met Primary Endpoint of Objective Response Rate with Durable Responses - WESTLAKE VILLAGE, Calif., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that the United States Food and Drug Administrat |
Genelux Corporation (NASDAQ:GNLX) most popular amongst retail investors who own 57%, insiders hold 25%Key Insights Significant control over Genelux by retail investors implies that the general public has more power to... |
Genelux Corporation Reports Third Quarter 2023 Financial Results and Provides General Business Updates- Expanded executive team as Lourie Zak appointed Chief Financial Officer - - Extended clinical focus on systemic administration in small cell lung cancer - - $29.9 million in cash and equivalents - WESTLAKE VILLAGE, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the third quarter of 2023 and provided general business updates. “The third quarter was highlighted by continued expansi |
12 Best Performing Biotech Stocks in 2023In this piece, we will take a look at the 12 best performing biotechnology stocks in 2023. If you want to skip our introduction to the biotechnology industry and some top players, then check out 5 Best Performing Biotech Stocks in 2023. Biotechnology is one of the hottest industries these days and one that has […] |
GNLX Price Returns
| 1-mo | -47.12% |
| 3-mo | -66.89% |
| 6-mo | -75.47% |
| 1-year | -85.94% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -75.73% |
| 2023 | N/A |
| 2022 | N/A |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...